Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $4.92M up 8056159% from its previous closing price of $2.11. In other words, the price has increased by $8056159 from its previous closing price. On the day, 8.06 million shares were traded. CTMX stock price reached its highest trading level at $2.375 during the session, while it also had its lowest trading level at $2.15.
Ratios:
For a deeper understanding of CytomX Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.11.
Piper Sandler Upgraded its Neutral to Overweight on May 28, 2024, whereas the target price for the stock was revised from $2.25 to $3.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 16 ’25 when Ogden Christopher sold 10,614 shares for $2.69 per share. The transaction valued at 28,540 led to the insider holds 226,271 shares of the business.
Ogden Christopher sold 1,641 shares of CTMX for $4,841 on Jun 13 ’25. The Chief Financial Officer now owns 199,385 shares after completing the transaction at $2.95 per share. On Jun 16 ’25, another insider, BELVIN MARCIA, who serves as the SVP, Chief Scientific Officer of the company, sold 13,884 shares for $2.69 each. As a result, the insider received 37,334 and left with 272,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 365502080 and an Enterprise Value of 115304400. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.68. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.48 while its Price-to-Book (P/B) ratio in mrq is 7.47. Its current Enterprise Value per Revenue stands at 0.781 whereas that against EBITDA is 3.063.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.12, which has changed by 0.7443609 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $3.10, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 38.90%, while the 200-Day Moving Average is calculated to be 105.20%.
Shares Statistics:
For the past three months, CTMX has traded an average of 4.92M shares per day and 3320090 over the past ten days. A total of 157.54M shares are outstanding, with a floating share count of 103.99M. Insiders hold about 33.81% of the company’s shares, while institutions hold 35.39% stake in the company. Shares short for CTMX as of 1748563200 were 18961903 with a Short Ratio of 3.86, compared to 1745971200 on 9743354. Therefore, it implies a Short% of Shares Outstanding of 18961903 and a Short% of Float of 12.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
